TW555533B - Condensed drink having an inflammation-suppressing effect and an infectious-disease-preventive effect - Google Patents
Condensed drink having an inflammation-suppressing effect and an infectious-disease-preventive effect Download PDFInfo
- Publication number
- TW555533B TW555533B TW89107388A TW89107388A TW555533B TW 555533 B TW555533 B TW 555533B TW 89107388 A TW89107388 A TW 89107388A TW 89107388 A TW89107388 A TW 89107388A TW 555533 B TW555533 B TW 555533B
- Authority
- TW
- Taiwan
- Prior art keywords
- concentrated
- present
- lactobacillus
- inflammation
- ministry
- Prior art date
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
- Fodder In General (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
555533 A7 ______B7_ 五、發明説明（1 ) 【發明之詳細說明】 【發明之技術領域】 (請先閲讀背面之注意事項再填寫本頁) 本發明是具抑制發炎病症作用及防禦感染病作用之濃 縮飮料’此外更詳細地說是共生培養保加利亞桿菌、顆粒 桿菌、嗜酸桿菌、乳酸桿菌、酵母菌5種類有益菌所得的 培養液濾液之濃縮液，具抑制發炎病症作用及防禦感染病 作用之濃縮飮料。 【先行技術】 一般市售的醫藥用飮劑、運動飮料或者淸涼飮料等各 種飮料製品，於這些飮料製品中有很多都添加人工的食品 添加物來增高其營養價値、嗜好性或者保存性等。 【發明所欲解決之課題】 這些人工的食品添加物對健康不能說是完全地無害， 對人體的有害性而成爲社會問題的案例也有發現。 經濟部智慧財產局員工消費合作社印製 本發明者從開始就不使用人工的添加物，而是從微生 物醱酵生產物來的飮料並不斷地專心從事重複之硏究。 【用以解決課題之手段】 其結果是由保加利亞桿菌、顆粒桿菌、嗜酸桿菌、乳 酸桿菌、酵母菌5種類有益菌以特定的組合共生培養所得 到的培養液之濾液開始，將含有良好的營養平衡之氨基 酸、維生素及礦物質等的有效成份，利用濃縮法濃縮並得 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐） 一 555533 A7 B7 1、發明説明（2 ) 到營養價値高的濃縮液，以及發現此濃縮液適宜作爲運動 飮料；因此，更不斷重複進行硏究發現，在此濃縮飮料中 A抑制發炎病症作用及防禦感染病作用之濃縮飮料，本發 明是基於如此的見解。 即與本發明相關之具抑制發炎病症作用及防禦感染病 作用之濃縮飮料是從共生培養保加利亞桿菌、顆粒桿菌、 嗜酸桿菌、乳酸桿菌、酵母菌5種類有益菌所得的培養液 濾液之濃縮液，不使用任何人造添加物者。 與本發明有關之濃縮飮料製造之際所用的有益菌表示 在表1中表示。 裝-- (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 -5- 本紙張尺度適用中國國家標準（CNS)A4規格（2i〇x 297公着） 555533555533 A7 ______B7_ 5. Description of the invention (1) [Detailed description of the invention] [Technical field of the invention] (Please read the precautions on the back before filling out this page) The invention is a condensate with the effect of inhibiting inflammation and preventing infection飮 料 'In addition, in more detail, it is a concentrated liquid of a culture broth obtained by co-cultivating 5 types of beneficial bacteria such as Bulgarian bacillus, granulobacteria, acidophilus, lactobacillus, and yeast, which has a function of inhibiting inflammatory diseases and preventing infections. Unexpectedly. [Advanced technology] Various commercially available elixir products such as pharmaceutical elixir, sports elixir, or desolate elixir. Many of these elixir products are supplemented with artificial food additives to increase their nutritional value, hobby, or preservation. . [Problems to be Solved by the Invention] These artificial food additives cannot be said to be completely harmless to health, and cases of harmfulness to the human body that have become social problems have also been discovered. Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs. The inventors did not use artificial additives from the beginning, but used materials derived from the fermentation of micro-organisms and continued to focus on repetitive research. [Means to solve the problem] As a result, the filtrate of a culture liquid obtained by co-cultivation of 5 types of beneficial bacteria of Bulgarian bacteria, granulobacteria, acidophilus, lactobacillus, and yeast in a specific combination will contain good The nutritionally balanced active ingredients such as amino acids, vitamins and minerals are concentrated by the concentration method to obtain the paper size applicable to the Chinese National Standard (CNS) A4 specification (210X297 mm)-555533 A7 B7 1. Description of the invention (2) to nutrition Highly concentrated liquid, and it is found that this concentrated liquid is suitable as a sports material; therefore, it is found that the concentrated material of A in this concentrated material inhibits the inflammatory disease and prevents the infection, and the present invention is based on this Insights. That is to say, the concentrated condensate with the effect of inhibiting inflammatory diseases and preventing infections related to the present invention is a concentrated liquid filtrate of a culture broth obtained from the symbiotic cultivation of 5 types of beneficial bacteria, including bacillus bulgaricus, granulobacteria, acidophilus, lactobacilli, and yeast , Do not use any artificial additives. Table 1 shows the beneficial bacteria used in the production of the concentrated congee related to the present invention. Packing-(Please read the notes on the back before filling out this page) Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs -5- This paper size applies to China National Standard (CNS) A4 (2i〇x 297) 555533
經濟部智慧財產局員工消費合作社印製 五、發明説明（3 ) 【表1】 用於濃縮飮料之製造的有益菌 1 Bac. Bulgaricus No.l 保加利亞桿菌 2 // 2 // 3 B a c. K o e r n c h e η No.l 顆粒桿菌 4 // 2 // 5 // 3 // 6 ff 4 ” 7 Bac.Acidophillus No.l 嗜酸桿菌 8 // 2 // 9 ” 3 ” 10 // 4 // 11 〃 5 // 12 〃 6 // 13 Micrococcus Lactis No.l 乳酸球菌 14 n 2 // 15 // 3 // 16 ” 4 // 17 Yeast No.l 酵母菌 18 // 2 // 19 // 3 // 20 // 4 // (請先閲讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐） -6 - 555533 A7 B7 五、發明説明（4 ) 本發明的濃縮飮料是從共生培養保加利亞桿菌、顆粒 桿菌 '嗜酸桿菌、乳酸桿菌、酵母菌5種類有益菌所得到 的培養液之濾液濃縮而成，並將這些有益菌分群，如同表 示在表2中所示。 【表2】 在濃縮飮料製造的第5工程中有益菌群的分類 第I群 1+3+9+13+17 第π群 - 2+4+10+14+18 第ΠΙ群 7+5+11+15+19 第IV群 8+6+12+16+20 ^ (注：數字是表示表1中的數字） 分析本發明的濃縮飮料，其內含有蛋白質、磷、_ 鈣、維生素B 1 、維生素B 2等，分析的結果表示在表 中〇 (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐）-7 - 555533Printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs. 5. Description of the invention (3) [Table 1] Bacteria used for the production of concentrated concoctions 1 Bac. Bulgaricus No.l Bulgarian bacteria 2 // 2 // 3 B a c. K oernche η No.l Granulobacillus 4 // 2 // 5 // 3 // 6 ff 4 ”7 Bac.Acidophillus No.l Acidophilus 8 // 2 // 9” 3 ”10 // 4 // 11 〃 5 // 12 〃 6 // 13 Micrococcus Lactis No.l Lactobacillus 14 n 2 // 15 // 3 // 16 ”4 // 17 Yeast No.l Yeast 18 // 2 // 19 // 3 // 20 // 4 // (Please read the notes on the back before filling out this page) This paper size is applicable to Chinese National Standard (CNS) A4 specification (210X297 mm) -6-555533 A7 B7 V. Description of the invention ( 4) The concentrated congee of the present invention is obtained by concentrating a filtrate of a culture liquid obtained by symbiotically culturing 5 types of beneficial bacteria such as bulgaric bacteria, granulobacteria, acidophilus, lactic acid bacteria, and yeast, and grouping these beneficial bacteria as shown Shown in Table 2. [Table 2] Classification of beneficial bacteria groups in the 5th process of concentrated concoction manufacturing Group 1 Group 1 + 3 + 9 + 13 + 17 Group π-2 + 4 + 10 + 14 + 18 Group ΠΙ 7 + 5 + 11 + 15 + 19 Group IV 8 + 6 + 12 + 16 + 20 ^ (Note: the numbers represent the numbers in Table 1) Analysis of the concentrated condiment according to the present invention, which contains protein, phosphorus, calcium, vitamin B 1 The results of the analysis are shown in the table. (Please read the notes on the back before filling out this page.) The paper size printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs applies the Chinese National Standard (CNS) A4 specifications ( 210X297 mm) -7-555533
7 r A C 五、發明説明（5 ) 【表3】 濃縮飮料的分析結果 分析試驗 項目 結果 注 分析方法 蛋白質 5.6°/〇 1 基耶達測氮法 磷 304 mg/100g 釩鉬酸吸光光度法 鐵 _1.72 mg/100g 鄰菲繞啉吸光光度法 鈣 165 mg/100g 過錳酸鉀容量法 維生素B! 0.03 mg/100g 2 高速液體層析法 維生素B2 〇. 12 mg/100g 高速液體層析法 全糖 11.9% 3 索默季氏測糖法 滴定酸度 87.8 4 pH 3.8 玻璃電極法 ϋϋ· i^n— ml ml ml I (請先閱讀背面之注意事項再填寫本頁} -訂 注1 ··氮•蛋白質換算數；6.25 注2 :維生素鹽酸鹽。 注3 :葡萄糖換算、加水分解條件；2.3%鹽酸、沸騰 浴中、2.5小時。 經濟部智慧財產局S工消費合作社印製 注4 :中和供試品l〇〇g所需1N鹼滴定ml數。 此外，本發明的濃縮飮料中以胺基酸而言，蘇胺酸、 纈胺酸、離胺酸、亮胺酸等的必須胺基酸之外，榖胺酸、 天冬胺酸、精胺酸等近2 0種的胺基酸得到確認。 但是本發明的濃縮飮料中，已知具抑制發炎病症作用 及防禦感染病作用之濃縮飮料，其作用以資料做詳細的說 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐） -8 - 555533 A7 ____ _B7__ 五、發明説明（6 ) 0月；lit 在本發明所說的發炎病症是關節炎及過敏反應 等’包含急性及慢性的各種炎症之槪念。 使用完全Freund佐劑（ajuvant) ( 0 . 1 mC的輕無機 油含0 · 3 m g之結核菌死菌的懸濁液）在大白鼠的後足 接種後5〜1 8日間大白鼠的腿會腫大，但此大白鼠在接 種1小時後，連續5日間每日2回1 0 0 %濃度之本發明 的濃縮飮料；此外，〇 . 5 % C . M . C ·(羥甲基纖維 素）及氫化可的松（Hydrocortison ; 3〇mg/Kg)同樣 地對大白鼠予以經口投與，這些結果表示在表4中。 (請先閲讀背面之注意事項再填寫本頁) 裝· 訂 經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐） -9 - 555533 A7 B7 五、發明説明（7 ) 【表4】 在大白鼠ajuvant (佐劑）誘發足躕浮腫抑制試驗 化合物 動物號碼 投與量ω 足躕浮腫量（i)和阻 礙率(％) 體重增加 (g) (18-0) 多發性 關節炎(c) PTNE (5-0) (18-14) 0.5 % C.M.C. 1 10ml/Kgx5 1.21 0.38 60 + + -- (b) 2 10ml/Kgx5 1.58 0.42 20 + + -- 3 10ml/Kgx5 1.09 0.38 60 + _j— 4 10ml/Kgx5 1.05 0.52 60 + + -- 5 10ml/Kgx5 1.27 0.30 35 -H--- 平均 1.24 0.40 47 本發明的 6 100% x5 0.86 0.22 40 — 濃縮飮料 7 100% x5 0.81 0.09 40 H---- 8 100% x5 1.12 0.11 60 H---- 9 100% x5 0.99 0.43 55 - + -- 10 100°/〇 x5 1.02 0.10 60 — 平均 0.96*(d) 0.19*(d) 51 mm 23 53 氫化可的松 11 30mg/Kgx5 0.93 0.42 40 + + -- 12 30mg/Kgx5 0.94 0.40 20 -H--- 13 30mg/Kgx5 0.71 0.30 5 + + -- 14 30mg/Kgx5 0.97 0.32 50 -H--- 15 30mg/Kgx5 0.80 0.26 40 — 平均 0.87**(d) 0.34 31 mm% 30 15 注：U) 0.5% C.M.C.液是依據相當於體重lKg的投與容量，濃縮飮料是依據相當於 體重lKg投與10 J之飮料濃度，此外徑化可的松是投與同體積相當於體重 lKg的藥物重量。 (請先閲讀背面之注意事項再填寫本頁) 裝·7 r AC V. Description of the invention (5) [Table 3] Analysis results of concentrated condensate Analytical test results Results Analytical method Protein 5.6 ° / 〇1 Kiyoda nitrogen method phosphorus 304 mg / 100g vanadium molybdic acid spectrophotometric iron _1.72 mg / 100g phenanthroline absorption spectrophotometry calcium 165 mg / 100g potassium permanganate volumetric method vitamin B! 0.03 mg / 100g 2 high-speed liquid chromatography vitamin B2 〇. 12 mg / 100g high-speed liquid chromatography Sugar 11.9% 3 Sommet's sugar method Titration acidity 87.8 4 pH 3.8 Glass electrode method ϋϋ i ^ n— ml ml ml I (Please read the notes on the back before filling this page} -Note 1 ·· Nitrogen • Number of protein conversions; 6.25 Note 2: Vitamin hydrochloride. Note 3: Conditions for glucose conversion and hydrolysis; 2.3% hydrochloric acid, in a boiling bath, 2.5 hours. Printed by S Industrial Consumers Cooperative, Intellectual Property Bureau, Ministry of Economic Affairs Note 4: Medium And 100 g of titration amount of 1N alkali titration required for the test product. In addition, in the concentrated feed of the present invention, in terms of amino acids, threonine, valine, lysine, leucine and other essential amines are required. In addition to basic acids, lysine, aspartic acid, arginine, etc. are nearly 20 Amino acids have been confirmed. However, in the concentrated feed of the present invention, it is known that the concentrated feed has the effect of inhibiting inflammatory diseases and preventing infections, and its effect is explained in detail based on the data. This paper standard applies Chinese National Standard (CNS) A4 Specifications (210X297 mm) -8-555533 A7 ____ _B7__ 5. Description of the invention (6) 0 months; lit In the present invention, the inflammatory conditions are arthritis and allergic reactions, etc., including the thoughts of acute and chronic inflammation The legs of rats were inoculated with Freund adjuvant (ajuvant) (a suspension of 0.1 mC of light inorganic oil containing 0.3 mg of tuberculosis bacteria) in the hind legs of rats for 5 to 18 days after inoculation. It will swell, but after 1 hour of inoculation, this rat has 100% concentration of the concentrated concoction of the present invention 2 times a day for 5 consecutive days; in addition, 0.5% C. M. C. (hydroxymethyl fiber And hydrocortisone (Hydrocortison; 30mg / Kg) were administered orally to rats, and the results are shown in Table 4. (Please read the precautions on the back before filling this page) Ordered by the Consumer Property Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs This paper scale applies Chinese National Standard (CNS) A4 specification (210X297 mm) -9-555533 A7 B7 V. Description of invention (7) [Table 4] Ajuvant (adjuvant) induced foot edema inhibition test compound animal in rats Number administration amount ω Foot plant edema amount (i) and obstruction rate (%) Weight gain (g) (18-0) Multiple arthritis (c) PTNE (5-0) (18-14) 0.5% CMC 1 10ml / Kgx5 1.21 0.38 60 + +-(b) 2 10ml / Kgx5 1.58 0.42 20 + +-3 10ml / Kgx5 1.09 0.38 60 + _j— 4 10ml / Kgx5 1.05 0.52 60 + +-5 10ml / Kgx5 1.27 0.30 35 -H --- average 1.24 0.40 47 6 of the present invention 100% x 5 0.86 0.22 40-concentrated feed 7 100% x 5 0.81 0.09 40 H ---- 8 100% x 5 1.12 0.11 60 H ---- 9 100 % x5 0.99 0.43 55-+-10 100 ° / 〇x5 1.02 0.10 60 — average 0.96 * (d) 0.19 * (d) 51 mm 23 53 hydrocortisone 11 30mg / Kgx5 0.93 0.42 40 + +-12 30mg / Kgx5 0.94 0.40 20 -H --- 13 30mg / Kgx5 0.71 0.30 5 + +-14 30mg / Kgx5 0.97 0.32 50 -H --- 15 30mg / Kgx5 0.80 0.26 40 — average 0.87 ** (d) 0.34 31 mm% 30 15 Note: U) 0.5% CMC solution is based on the dosing volume equivalent to 1Kg of body weight. Concentrated sauce is based on the concentration of dosing equivalent to 1Kg of body weight and 10 J. The outer diameter of cortisone is equivalent to 1Kg of body weight. Of drug weight. (Please read the notes on the back before filling this page)
、1T 經濟部智慈財產局員工消費合作社印製 (b) C.M.C·羥甲基纖維素 (c) P:前足T:尾部N:首部E:耳 (d) *:p<0.05 **:p<0.01 t 檢定 本紙張尺度適用中國國家標準（CNS ) Α4規格（210X297公釐） -10 - 555533 A7 B7 五、發明説明（8 ) (請先閲讀背面之注意事項再填寫本頁) 從表4可以知道本發明的濃縮飮料利用經口投與的方 式，可以有效地減少前記大白鼠的腳腫大，防止腳腫大是 急性期（從第0日至第5日，p<0 · 05，t檢定）及 後期（從第14日至第18日，p<0 · 05)兩者均觀 察，針對此點氫化可的松在急性期是被認爲有效的（p < 〇 . 0 1，t檢定）；但在後期並無效果。 另一方面’發炎病症從後足向前足轉移來看，經口投 與〇 . 5% C ·Μ· C .時爲4/5，而本發明的濃縮飮 料經口投與時爲2 / 5 (參照表4的Ρ項），此外發炎病 症向尾部轉移來看，經口投與〇 · 5% C ·Μ. C ·時爲 5 / 5，而本發明的濃縮飮料經口投與時爲1 / 5 (參照 表4的Τ項），由此可知本發明的濃縮飮料發炎病症向兩 部份的轉移可被抑制。 經口投與氫化可的松時，可以抑制發炎病症向前足的 轉移（經口投與〇 · 5% C ·Μ· C .時爲4/5，而本 發明的濃縮飮料經口投與時爲2 / 5 ，參照表4的Ρ 經濟部智慧財產局員工消費合作社印製 項）’但是無法抑制發炎病症向尾部轉移（經口投與 〇· 5 % c · M _ C .時爲4 / 5，而本發明的濃縮飮料 經口投與時爲1 / 5，參照表4的Τ項）。 此外，鹿角菜（Carrageenan ) ( 1 %懸濁液）〇 · 1 -e ’在大白鼠的後趾內投與進行鹿角菜誘發足躕浮腫試 驗’在投與鹿角菜3小時後大白鼠的後足發生腫大，此大 白鼠在鹿角菜投與一小時前給予一回本發明1 〇 〇 %濃度 的濃縮飮料；此外，蒸餾水（2 〇 4/ K g )、阿斯匹靈 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐）-11 - 555533 A7 B7 五、發明説明（9 )(1 5 0 m g / K g )經口投與於其他的大白鼠 表示在表5中。 其結果 (請先閲讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐） -12 - 555533 A7 B7 五、發明説明（1〇 ) 【表5】 大白鼠之鹿角菜誘發足 躕浮腫抑制試驗 化合物 投與量ω 動物 數 後肢足躕浮腫量 (χθ.01 τηί ) ρ 値(b) 右 左 差異 蒸餾水 20ml/Kg 6 101·5 土 2.5 196.8 土 2.7 93.7 土 1.6 本發明的 濃縮飮料 100% 6 105.4 土 3.8 167.6 ±6.3 62.2 土 6.7 ρ<0·01 本發明的 濃縮飮料 50% 5 107.2 ± 2.4 201.7 土 2.6 94.5 土 1.7 ρ<0.05 阿斯匹靈 150mg/Kg 6 107.0 土 2.7 171.0 土 3.0 64.0 ±1.8 ρ<0·01 (請先閲讀背面之注意事項再填寫本頁) 注：（a)蒸簡水是依據相當於體重lKg的投與容量，濃縮飮料是依據相當於體重 IKg投與20 J之飮料濃度，阿斯匹靈是投與同體積相當於體重lKg的藥物 重量。 (b)使用Dunnet多重比較測試，進行統計處理。P値是從後肢浮腫量的測試樣品 和蒸觀水群之比較所算出。 經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐） -13 - 555533 A7 ________B7_ L、發明説明（11 ) 從表5可以知道經口給予本發明的濃縮飮料時，被認 爲有抗發炎病症的效果。 其次，利用皮膚內反應體（I g E )性抗卵白蛋白血 胃（〇 · 5 W )在2 4小時前感染大白鼠進行被動性皮膚 Analylaxis試驗；此大白鼠的皮膚因卵白蛋白在3 〇分鐘後 胃$過敏反應，此大白鼠在卵白蛋白投與1小時前單回經 D &與本發明1 0 0 %濃度和5 0 %濃度的濃縮飮料；此 外’蒸餾水（2 0 J/K g )、阿斯匹靈（3 m g / K g )同樣地對大白鼠經口投與，其結果表示在表6中。 【表6】 辦衣-- (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 對IgE誘發皮膚反應之抑制試驗 化合物 投與量（a) 動物數 IgE反應 皮膚膨疹的大 小（mm) 阻礙率（％) 蒸餾水 20ml/Kg 3 30 本發明的 濃縮飮料 100% 3 12 60 本發明的 濃縮飮料 50% 3 30 0 噻庚烷 3mg/Kg 3 2 93 注：（a)蒸餾水是依據相當於體重iKg的投與容量，濃縮飮 料是依據相當於體重lKg投與20 i之飮料濃度， 噻庚烷是投與同體積相當於體重lKg的藥物重量。 訂 線 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐） -14 - 5555331T Printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs (b) CMC · hydroxymethyl cellulose (c) P: Forefoot T: Tail N: Head E: Ear (d) *: p < 0.05 **: p < 0.01 t verification This paper size applies the Chinese National Standard (CNS) A4 specification (210X297 mm) -10-555533 A7 B7 V. Description of the invention (8) (Please read the precautions on the back before filling this page) From Table 4 It can be known that the concentrated tincture of the present invention can effectively reduce the swelling of the feet of the rat, and prevent the swelling of the feet from the acute stage (from day 0 to day 5, p < 0.05, t test) and later (from the 14th to the 18th, p < 0 · 05) were observed, for which point hydrocortisone was considered effective in the acute phase (p < 〇. 0 1 , T test); but has no effect in the later stage. On the other hand, from the perspective of hindfoot and forward foot metastasis, the oral administration of 0.5% C · M · C is 4/5, and the concentrated material of the present invention is 2/5 when administered orally. (Refer to item P in Table 4). In addition, when the inflammatory condition is transferred to the tail, it is 5/5 when administered orally at 0.5% C · M · C ·, and when the concentrated material of the present invention is administered orally 1/5 (refer to item T in Table 4). It can be seen from this that the transfer of the inflammatory condition of the concentrated condensate of the present invention to two parts can be suppressed. When hydrocortisone is administered orally, metastasis of the inflammatory condition to the front foot can be inhibited (4.5% when administered orally at 0.5% C · M · C. However, when the concentrated material of the present invention is administered orally 2/5, refer to Table 4 of the P printed by the Consumers ’Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs) but cannot inhibit the transfer of inflammatory conditions to the tail (oral administration is 0.5% c · M _ C. 4 / 5, and the concentrated condensed material of the present invention is 1/5 when administered orally, refer to item T in Table 4). In addition, Carrageenan (1% suspension) 〇-1 -e 'administered in the hind toe of the rat to perform the carrageenan-induced plantar edema test' in the rear of the rat 3 hours after the administration of the carrageen Swelling of the foot occurred. The rat was given a concentrated condiment of 100% concentration according to the present invention one hour before the carrageen was administered. In addition, distilled water (204 / K g) and aspirin paper were applicable. Chinese National Standard (CNS) A4 specification (210X297 mm) -11-555533 A7 B7 V. Description of the invention (9) (1 50 mg / K g) Orally administered to other rats is shown in Table 5. The result (please read the notes on the back before filling this page) The paper size printed by the Employees' Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs applies the Chinese National Standard (CNS) A4 specification (210X297 mm) -12-555533 A7 B7 V. Description of the invention (10) [Table 5] The amount of test compound administration of carrageenan-induced plantar edema inhibition in rats ω Number of animals hindfoot plantar edema (χθ.01 τηί) ρ 値 (b) right and left differential distilled water 20ml / Kg 6 101 · 5 soil 2.5 196.8 soil 2.7 93.7 soil 1.6 100% of concentrated concentrate of the present invention 6 105.4 soil 3.8 167.6 ± 6.3 62.2 soil 6.7 ρ < 0 · 01 50% of concentrated concentrate of the present invention 5 107.2 ± 2.4 201.7 soil 2.6 94.5 soil 1.7 ρ < 0.05 aspirin 150mg / Kg 6 107.0 soil 2.7 171.0 soil 3.0 64.0 ± 1.8 ρ < 0 · 01 (Please read the precautions on the back before filling this page) Note: (a) Steaming water is based on the equivalent of The dosage volume of body weight is 1Kg. Concentrated material is based on the concentration of 20K of body weight corresponding to IKg of body weight, and aspirin is administered with the same volume of drug as the weight of 1Kg. (b) Use Dunnet multiple comparison test for statistical processing. P 値 is calculated from the comparison between the test sample of hindlimb edema and the steamed water group. Printed by the Consumers' Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs, the paper size is applicable to the Chinese National Standard (CNS) A4 specification (210X297 mm) -13-555533 A7 ________B7_ L. Description of the invention (11) It can be known from Table 5 that the invention was given orally It is believed to have an anti-inflammatory effect when it is concentrated. Second, the intradermal reactant (I g E) anti-ovalbumin blood stomach (0.5 W) was used to infect rats 24 hours before the passive skin Analylaxis test; the skin of this rat was affected by ovalbumin at 3.0%. After an allergic reaction to the stomach after 1 minute, this rat was treated with D & and the concentrated concentrate of 100% and 50% concentration according to the present invention for 1 hour before ovalbumin administration; in addition, 'distilled water (2 0 J / K g), aspirin (3 mg / Kg) was administered orally to rats, and the results are shown in Table 6. [Table 6] Clothing-(Please read the precautions on the back before filling out this page) Printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs on the dosage of test compounds for inhibiting IgE-induced skin reactions (a) Number of animals IgE response Size of skin eczema (mm) Obstruction rate (%) Distilled water 20ml / Kg 3 30 Concentrated sauce of the present invention 100% 3 12 60 Concentrated sauce of the present invention 50% 3 30 0 Thioheptane 3mg / Kg 3 2 93 Note: ( a) Distilled water is based on the dosing capacity equivalent to body weight iKg, concentrated distillate is based on the concentration of distillate equivalent to 1 kg body weight and 20 i, and thioheptane is administered to the same volume of drug equivalent to 1 kg body weight. Dimensions This paper is sized for China National Standard (CNS) A4 (210X297 mm) -14-555533
7 B 五、發明説明（12 ) 從表6可以知道經口投與本發明1 〇 〇 %濃度濃縮飮 料時，被認爲可有效地阻止因卵白蛋白而生成的過敏反 應。 另外，大白鼠在2 4小時前感染皮膚內反應體（ I g E )性抗卵白蛋白血淸（〇 · 5 J )，計算阻害率 (% )的話，在卵白蛋白（1 m g )加入伊文氏藍（ 5 mg)向靜脈內投與，記錄30分後皮膚膨疹反應。 此外，對用組織胺.二磷酸（〇 · 〇 5 J中 3 0 m g )接種的大白鼠進行被動性的皮膚Analylaxis試 驗，在接種1 0分後的大白鼠之皮膚可見到膨疹；對此大 白鼠經口投與本發明1 0 0 %濃度濃縮飮料；此外，蒸餾 水（2 0 / K g )、噻庚烷抗組織胺藥（3 m g / K g )同樣地對大白鼠經口投與，其結果表示在表7中。 【表7】 (請先閲讀背面之注意事項再填寫本頁) •裝· 經濟部智慧財產局員工消費合作社印製 大白鼠針對組織胺誘發皮膚反應的抑制試驗 _ 化合物 投與量（a) 動物數 組織胺反應 皮膚膨疹的 阻礙率（％) 大小（mm) 蒸餾水 20ml/Kg 3 30 本發明的 100% 3 30 0 濃縮飮料 噻庚烷 3mg/Kg 3 14 53 注：U)蒸餾水是依據相當於體重lKg的投與容量，濃縮飮 料是依據相當於體重lKg投與20 J之飮料濃度’7 B V. Description of the invention (12) From Table 6, it can be known that when the 100% concentrated concentrate of the present invention is orally administered, it is considered that it can effectively prevent the allergic reaction caused by ovalbumin. In addition, rats were infected with intra-dermal reactant (IgE) anti-ovalbumin hemoglobin (0.5 J) 24 hours before, and the blocking rate (%) was calculated by adding Evans to ovalbumin (1 mg). Blue (5 mg) was administered intravenously, and a skin eczema response was recorded 30 minutes later. In addition, a passive skin Analylaxis test was performed on rats inoculated with histamine diphosphate (30 mg in 0.05 mg J), and rash was seen on the skin of rats after 10 minutes of inoculation; The rats were orally administered with the 100% concentrated concentrated feed according to the present invention; in addition, distilled water (20 / Kg) and thioheptane antihistamine (3 mg / Kg) were also orally administered to rats, The results are shown in Table 7. [Table 7] (Please read the precautions on the back before filling out this page) • Equipment · Printed by the Intellectual Property Office of the Ministry of Economic Affairs and the Consumer Cooperatives printed on the inhibition of histamine-induced skin reactions in rats _ Compound dosage (a) Animals Number of Histamine Response Obstructive Rate of Skin Eczema (%) Size (mm) Distilled Water 20ml / Kg 3 30 100% of the invention 3 30 0 Concentrated thiathane 3mg / Kg 3 14 53 Note: U) Distilled water is equivalent to The weight of lKg is given, and the concentrate is based on the concentration of 20 kg of lKg.
本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐） -15 - 555533 Α7 Β7 五、發明説明（13 ) 噻庚烷是投與同體積相當於體重IKg的藥物重量。 從表7可以知道用本發明的濃縮飮料被認爲對組織胺 並無作用。 另外’計算阻礙率（％ )的話，皮膚內組織胺.二磷 酸（0 · 0 5 J中3 0 m g )，在接種1 〇分鐘後，記錄 減少的皮膚膨疹。 從以上可以知道本發明的濃縮飮料中，關節炎及過敏 反應等有抑制急性及慢性的各種發炎病症的作用。 本發明的濃縮飮料是從酵母菌和乳酸菌，共生培養保 加利亞桿菌、顆粒桿菌、嗜酸桿菌、乳酸桿菌、酵母菌5 種類有益菌所得到的培養液，且因爲是濃縮微生物醱酵生 產物的濾液全不使用人造添加物，所以作爲健康飮料最爲 適合。 【發明實施之形態】 以下，舉出具體實例更予以詳細地說明本發明的濃縮 飮料。 本發明的濃縮飮料是從共生培養保加利亞桿菌、顆粒 桿菌、嗜酸桿菌、乳酸桿菌、酵母菌5種類有益菌所得培 養液之濾液濃縮而成。 使用的培養基，使用大豆來的豆漿最爲適合，在乳酸 菌的培養一般多用牛乳’但考慮牛乳的不均一性、經時變 化性、其生產過程中藥劑等的使用混入等’再加上一切人 本紙張尺度適用中國國家標準（CNS ) A4規格（210x297公釐） -16 — I---------1衣-- (請先閲讀背面之注意事項再填寫本頁) 訂 經濟部智慧財產局員工消費合作社印製 555533 A7The size of this paper is applicable to Chinese National Standard (CNS) A4 (210X297 mm) -15-555533 A7 B7 V. Description of the invention (13) Thioheptane is the weight of a drug equivalent to IKg of the same volume. From Table 7, it can be known that the concentrated tincture using the present invention is considered to have no effect on histamine. In addition, when calculating the obstruction rate (%), histamine in the skin. Diphosphonic acid (30 mg in 0. 05 J) was recorded, and reduced skin rash was recorded 10 minutes after the inoculation. From the above, it is understood that the concentrated tincture of the present invention has the effects of suppressing various acute and chronic inflammatory conditions, such as arthritis and allergic reactions. The concentrated condiment according to the present invention is a culture liquid obtained by symbiotically culturing 5 types of beneficial bacteria such as bacillus bacillus, granulobacteria, acidophilus, lactobacillus, and yeast from yeast and lactic acid bacteria, and because it is a filtrate of concentrated microbial fermentation product No artificial additives are used, so it is most suitable as a healthy ingredient. [Embodiments of the Invention] Hereinafter, the concentrated dumplings of the present invention will be described in more detail with specific examples. The concentrated condiment according to the present invention is obtained by concentrating a filtrate of a culture liquid obtained by symbiotically cultivating five types of beneficial bacteria such as Bulgarian bacillus, granulobacteria, acidophilus, lactobacillus, and yeast. The medium used is soybean milk, which is the most suitable medium. Generally, milk is often used in the cultivation of lactic acid bacteria. 'But considering the non-uniformity of milk, the change with time, the use of pharmaceuticals, etc. in the production process, plus everyone This paper size applies to China National Standard (CNS) A4 (210x297 mm) -16 — I --------- 1 clothing-(Please read the precautions on the back before filling this page) Order the Ministry of Economic Affairs Printed by the Intellectual Property Bureau Employee Consumer Cooperative 555533 A7
經濟部智慧財產局員工消費合作社印製 五、發明説明（14 ) 工添加物均不使用的自然飮料之觀點來看，最適合做爲培 養基的是自然食品，而且使用保證完全無農藥的大豆（愛 荷華州產）來的豆乳最爲適合。 此外，本發明的濃縮飮料，在培養完成之後加熱殺 菌，並除去菌體；此分離菌體之培養液濾液濃縮至約i 5 分之1所生成的爲最佳。 其次’舉出本發明濃縮飮料的製造方法之一例，其例 是特許1962512號（特公平6 一95914號）。 (1 )第1步驟（特殊洋菜培養基的製造） 精緻之天然洋菜中，加入用蒸餾水煮的牛肉、昆布所 得到的湯液’鹽分和有益菌培養液，製造特殊洋菜培養 基。 (2 )第2步驟（有益菌之純粹培養） 在第1工程中所製造的特殊洋菜培養基中移植各種有 益菌，放入3 9 °C恆溫器中培養4 8〜5 0小時。 (3 )第3步驟（特殊豆乳培養基之製造） 從大豆除去脂肪加入蒸餾水煮沸7 0〜1 1 〇分後， 濾過的豆乳濾液中加入鹽、三溫糖及有益菌培養液，製造 特殊豆乳培養基。· (4 )第4步驟（用有益菌之特殊豆乳培養基來純粹培 養） 在第3步驟中所製造的特殊豆乳培養基中移植在第2 步驟中純粹培養的各種有益菌，放入3 9 °C恆溫器中培養 4 8〜5 0小時。 Γ請先閱讀背面之注意事^再填寫本頁〕 -訂Printed by the Consumers ’Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs V. Invention Description (14) From the viewpoint of natural additives that are not used in industrial additives, natural food is the most suitable as a culture medium, and soybeans that are completely free of pesticides are used ( Soymilk from Iowa) is the most suitable. In addition, the concentrated mash of the present invention is sterilized by heating after the completion of the culture, and the bacterial cells are removed; the filtrate of the culture liquid of the isolated bacterial cells is preferably concentrated to about 1/5 of i 5. Next, an example of a method for manufacturing the concentrated tartar of the present invention is given, and an example thereof is Patent No. 1962512 (Trade Fair No. 6-95914). (1) Step 1 (manufacturing of special agar culture medium) The refined natural agar is added with the soup 'salt and beneficial bacteria culture liquid obtained from beef boiled with distilled water and kumbu to produce a special agar culture medium. (2) Step 2 (Pure cultivation of beneficial bacteria) Various beneficial bacteria are transplanted into the special agar culture medium produced in the first process, and cultured in a thermostat at 39 ° C for 48 to 50 hours. (3) Step 3 (manufacturing of special soymilk culture medium) After removing fat from soybeans and boiling with distilled water for 70 to 110 minutes, the filtered soymilk filtrate is added with salt, tritemperature sugar and beneficial bacteria culture solution to produce special soymilk culture medium. . · (4) Step 4 (Pure culture with special soymilk culture medium for beneficial bacteria) The special soymilk culture medium produced in step 3 is transplanted with various beneficial bacteria purely cultured in step 2 and placed at 39 ° C Incubate in a thermostat for 48 to 50 hours. Γ Please read the notes on the back ^ before filling this page]-Order
-1 - a I- - I I 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐） -17 - 555533 經濟部智慧財產局員工消費合作社印製 A7 _ —_ B7 ____ 五、發明説明（15 ) (5 )第5步驟（有益菌之中量馴化培養） 在第3步驟中所得到的特殊豆乳培養基中，將在第4 步驟中所製造好的純粹培養有益菌分群，並對其群移植在 3 9 °C中馴化培養4 8〜5 0小時。 (6 )第6步驟（有益菌之工業共生培養） 在第3步驟中所得到的特殊豆乳培養基1 3升中，根 據第5步驟所製造出的群一些移植馴化培養之生菌，在 4 0°C中一起進行共生培養1 〇 〇〜1 2 0小時。 (7 )第7步驟（培養之停止及濃縮） 在第6步驟中製造的共生培養液，在1 〇 〇°C中加熱 3 0分，使生菌的繁殖停止，其次分離除去生菌所得到的 濾液濃縮至約1 5分之1 (去除9 3〜9 6 %的水份）。 (8 )第8步驟（熟成） 在第7步驟所得的濃縮液，在1 7 °C靜置3個月以上 使其熟成。 根據以上的步驟所得之生產物封入容器，經過法定加 熱作爲濃縮飮料製品。 本發明濃縮飮料是經由如此的步驟所製造出來，要點 可說是酵母菌和乳酸菌之發酵生產物，也可說是無添加人 工添加物之自然健康飮料。 此濃縮飮料中，如上述之抑制炎症作用外，飮用此物 後能抑制關節炎及過敏反應等之急性及慢性之各種炎症。 還有，本發明濃縮飮料有加成免疫抑制作用，在使用小鼠 模式in vivo (生體內試驗）進行有關本發明濃縮飮料之免 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐） -18 - (請先閱讀背面之注意事項再填寫本頁) 裝. 訂 線 555533 A7 B7 五、發明説明（16 ) 疫抑制試驗時，和動物感染的對照比較起來提升了 2 〇 % 的生存率，用免疫抑制劑（環磷醯胺）處理在免疫抑制試 驗中生存率增加了 3 0 %，從這些的結果可知本發明濃縮 飮料中有抑制免疫作用。 以下，簡單的說明，有關免疫抑制試驗。 (免疫調整試驗）-1-a I--II This paper size applies the Chinese National Standard (CNS) A4 specification (210X297 mm) -17-555533 Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs A7 _ —_ B7 ____ V. Description of the invention ( 15) (5) Step 5 (domesticated domesticated culture of beneficial bacteria) In the special soymilk medium obtained in step 3, the purely cultured beneficial bacteria group produced in step 4 is divided into groups. The transplantation was domesticated and cultured at 39 ° C for 48 to 50 hours. (6) Step 6 (Industrial Symbiotic Culture of Beneficial Bacteria) Among the 13 liters of special soymilk culture medium obtained in step 3, some of the transplanted and domesticated cultured bacteria produced in the group according to step 5 are grown at 40%. Symbiotic cultures were performed together at ° C for 100 to 120 hours. (7) Step 7 (Stopping and Concentration of Culture) The symbiotic culture liquid produced in Step 6 is heated at 100 ° C for 30 minutes to stop the growth of bacterial growth, followed by separation and removal of bacterial growth. The filtrate was concentrated to about 1/5 (removing 9 3-96% of water). (8) Step 8 (Maturation) The concentrated liquid obtained in Step 7 is allowed to stand at 17 ° C for 3 months or more to mature. The product obtained according to the above steps is sealed in a container and subjected to legal heating as a concentrated fodder product. The concentrated seasoning of the present invention is manufactured through such steps. The main points can be said to be fermented products of yeast and lactic acid bacteria, and it can also be said to be a natural healthy seasoning without added artificial additives. In addition to the above-mentioned inflammatory inhibitory effects in this concentrated condiment, the use of this condensate can inhibit acute and chronic inflammations such as arthritis and allergic reactions. In addition, the concentrated condensate of the present invention has an additive immunosuppressive effect. The exemption of the concentrated condensate of the present invention is performed in a mouse mode in vivo. The paper size is applicable to the Chinese National Standard (CNS) A4 specification (210X297 mm). ) -18-(Please read the precautions on the back before filling in this page). Binding. 555533 A7 B7 V. Description of the invention (16) During the epidemic suppression test, compared with the control of animal infection, it has improved the survival by 20%. Rate, treatment with an immunosuppressive agent (cyclophosphamide) increased the survival rate by 30% in the immunosuppressive test. From these results, it can be seen that the concentrated feed of the present invention has an immunosuppressive effect. The following briefly describes the immunosuppression test. (Immune adjustment test)
Sublow液體培養基（Difco，底特律，美國密西根 州）’（以下略稱爲S B培養基）作爲培養用，Candida albicans (AT CC1 0231) 37 °C，16 小時通氣培 養取得對數期之增殖菌，期待含有9 0〜1 0 〇 %之小鼠 死亡率的黴菌量之接種物是用磷酸緩衝液來稀釋（以下略 稱爲P B S ) —夜培養液調製而成，接種物所生成的黴菌 數是用爲5 5 0 n m的濁度爲主來，測定接種培養連續稀 釋液於S B洋菜培養基上做正確的測定，靜脈注射稀釋接 種物0 · 2 2於雄性I C R小鼠（5週大，約2 4 g )， 接種量一隻小鼠大約從1 · 5 X 1 0 7到2 . 0 X 1 0 7 C F U。 (免疫回復試驗） 前記Sublow液體培養基做作爲培養用，Candida albicans (ATCC1 023 1)在 37°C 通氣培養 1 6 小 時，取得對數期之增殖菌，含有黴菌之接種物期待正常小 鼠有0〜1 0 %的死亡率，免疫抑制小鼠有7 0 %的死亡 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐） -19 - 批衣-- (請先閲讀背面之注意事項再填寫本頁) 訂 !·線 經濟部智慧財產局員工消費合作社印製 555533 A7 B7 經濟部智慧財產局員工消費合作社印製 五、發明説明（17 ) 率，此接種物是用P B S稀釋液培養液調製而成；接種物 生存之黴菌數是用5 5 0 n m的濁度爲主來測定，接種培 養連續稀釋液於S Β洋菜培養皿上，正確地測定靜脈注射 稀釋接種物〇 · 2 W於雄性I C R小鼠（4週大，約 2 0 g )，接種量一隻小鼠大約從6 X 1 0 6到8 X 1 〇 6 C F U。 本發明的濃縮飮料和Azimexone用P B S ( p Η 7 · 4 )溶解稀釋，於第1、3、5日投與腹腔投與 0 · 8 J之測試化合物或P B S於雄性I C R小鼠（i . p _ )，免疫抑制劑（環磷醯胺；3 0 m g / K g )，於 第2、4、6日經口投與（p . 〇 ·)，在第7日對小鼠 接種0 · 2 J的Candida albicans稀釋接種物，接著在接種 後1 0日間記錄生存動物。 (in vivo 效果） 在免疫調整試驗中，各投與群使用1 〇匹的I c R小 鼠，用腹腔內投與（i . P ·)對各小鼠投與1 %量和 〇 · 1 %量本發明的濃縮飮料及Azimexone ( 1 0 0 m g / Kg)，在進行1 〇回的實驗裡所累積每日死亡數並統計 之。 PB S對照群中有8 9%的死亡率（1 〇 〇匹之中8 9匹死亡），但投與本發明的濃縮飮料時，約減少至7 0 % (1%量投與時，100匹之中70匹死亡，0 · 1% 量投與時’ 1 0 〇匹之中7 2匹），Azimexone投與時的死 (請先閱讀背面之注意事項再填寫本頁) 裝· 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐） -20 - 555533 A7 _B7___ 五、發明説明（18 ) 亡率是82%(50匹之中41匹死亡）。 此外，在免疫回復試驗中，各個投與群使用1 〇隻 I C R對各小鼠腹腔內給予（i · P · ) 1 %和0 · 1 % 濃度之本發明濃縮飮料或者1 0 0 m g / K g的Azimexone 進行8回的實驗後給予每日死亡數。 P B S和（環磷醯胺）投與對照群是7 5 %的死亡率 (8 0匹之中6 0匹死亡），但投與本發明濃縮飮料時減 少至35%和43% (投與1%濃度時，80匹之中28 匹死亡，投與0 · 1%濃度時，80匹之中34匹死 亡），Azimexone投與群的死亡率是5 0% ( 8 0匹之中4 0匹死亡）。 像這樣在免疫調整試驗中，本發明的濃縮飮料和感染 動物之對照比較提升2 0 %的生存率，此外用環磷醯胺處 理針對抑制免疫之回復試驗中有上昇3 0 %〜4 0 %的生 存率。 從以上可以知道本發明的濃縮飮料中有免疫調整、回 復作用，也就是說免疫機能在正常的場合和抑制狀態時， 對於黴菌感染有調整免疫回復之作用，所以可能可以防禦 各種感染症及日和見感染症。 【發明之效果】 在本發明的濃縮飮料中不僅能夠抑制發炎病症的作 用’而且飮用此飮料，在關節炎及過敏反應等抑制急性及 慢性的各種發炎病症’從免疫調整、回復作用也有來看， 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公餐) 721^---—- (請先閲讀背面之注意事項再填寫本頁) 裝· 訂 經濟部智慧財產局員工消費合作社印製 555533 A7 B7五、發明説明（19 )能夠防禦各種感染症或日常見的感染症。 (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐） -22 -Sublow liquid medium (Difco, Detroit, Michigan, USA) '(hereinafter referred to as SB medium) is used for culture. Candida albicans (AT CC1 0231) is cultured at 37 ° C for 16 hours to obtain logarithmic proliferative bacteria. The mold inoculum of 90% to 100% mouse mortality is diluted with phosphate buffer solution (hereinafter abbreviated as PBS)-prepared from a night culture solution. The number of molds produced by the inoculum is used as The turbidity at 5 50 nm is mainly determined by measuring the serial dilution of inoculated culture on SB agar culture medium for correct determination. The diluted inoculum 0 · 2 2 is injected intravenously in male ICR mice (5 weeks old, about 2 4 g), the inoculation amount of a mouse is about 1.5 X 107 to 2.0 X 107 CFU. (Immune recovery test) The Sublow liquid medium was used for culture. Candida albicans (ATCC1 023 1) was aerated and cultured at 37 ° C for 16 hours to obtain logarithmic proliferative bacteria. The inoculum containing molds is expected to have normal mice with 0 ~ 10% death rate, 70% death in immunosuppressed mice. The paper size applies the Chinese National Standard (CNS) A4 specification (210X297 mm). -19-Approval-(Please read the precautions on the back before reading) (Fill in this page) Order! Printed by the Consumers ’Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs 555533 A7 B7 Printed by the Consumers’ Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs 5. Description of the invention (17) rate, this inoculum is diluted with PBS culture solution Prepared; the number of molds in the inoculum is measured with a turbidity of 5 50 nm, and serial dilutions of the inoculation culture are placed on a SB agar dish, and the intravenously diluted inoculum is measured correctly. 2 W In male ICR mice (4 weeks old, about 20 g), the inoculation amount of one mouse was about 6 X 106 to 8 X 106 CFU. The concentrated gizzard and Azimexone of the present invention were dissolved and diluted with PBS (p Η 7 · 4), and the test compound was administered intraperitoneally on the 1st, 3rd, and 5th days or PBS was administered to male ICR mice (i.p. _), An immunosuppressant (cyclophosphamide; 30 mg / K g), was orally administered on days 2, 4, and 6 (p. 〇), and mice were inoculated on day 7 with 0.2 J's Candida albicans diluted the inoculum, followed by recording live animals 10 days after inoculation. (In vivo effect) In the immune adjustment test, 10 IcR mice were used in each administration group, and 1% and 0.1 were administered to each mouse by intraperitoneal administration (i.P.). The amount of the concentrated congee of the present invention and Azimexone (100 mg / Kg) in the amount of 10% were accumulated and the daily deaths were counted in 10 experiments. The PB S control group had a mortality rate of 89% (89 out of 100 deaths), but when the concentrated concoction of the present invention was administered, it was reduced to approximately 70% (100% when administered in a 1% amount). 70 of the horses died, and 72% of the 100% were administered at the rate of 0.1%; 72 died of Azimexone when administered (please read the precautions on the back before filling this page). The scale applies to the Chinese National Standard (CNS) A4 specification (210X297 mm) -20-555533 A7 _B7___ V. Description of the invention (18) The mortality rate is 82% (41 out of 50). In addition, in the immune recovery test, each administration group used 10 ICRs to intraperitoneally give each mouse (i · P ·) 1% and 0.1% concentrations of the concentrated concentrate of the present invention or 100 mg / K g. Azimexone gave 8 deaths after 8 experiments. Administration of PBS and (cyclophosphamide) resulted in a 75% mortality rate (60 out of 80 deaths), but was reduced to 35% and 43% (administration of 1) At a concentration of 28%, 28 of 80 died, and at a concentration of 0.1%, 34 of 80 died. The Azimexone administration group had a mortality rate of 50% (40 out of 80). death). In this way, in the immune adjustment test, the concentrated feed of the present invention and the control of infected animals improved the survival rate by 20%, and in addition, the treatment with cyclophosphamide treatment for the suppression of immune response increased by 30% to 40%. Survival rate. From the above, it can be known that the concentrated tincture of the present invention has an immune adjusting and restoring effect, that is, the immune function can adjust the immune restoring effect on fungal infections in normal occasions and in a suppressed state, so it may be able to prevent various infections and daily diseases. Infections. [Effects of the invention] The concentrated food of the present invention can not only suppress the effects of inflammatory conditions', but also use this material to suppress various acute and chronic inflammatory conditions such as arthritis and allergic reactions. It also has immune adjustment and recovery effects. See, this paper size applies Chinese National Standard (CNS) A4 specification (210X297 meals) 721 ^ ------ (Please read the precautions on the back before filling this page) Binding and Ordering Staff Consumer Cooperatives, Intellectual Property Bureau, Ministry of Economic Affairs Printing 555533 A7 B7 V. Description of the invention (19) It can prevent various infections or common infections. (Please read the notes on the back before filling out this page) Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs This paper applies the Chinese National Standard (CNS) A4 specification (210X297 mm) -22-
Claims (1)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP32007898A JP3276929B2 (en) | 1998-10-22 | 1998-10-22 | Concentrated beverage with anti-inflammatory and anti-infective effects |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW555533B true TW555533B (en) | 2003-10-01 |
Family
ID=18117481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW89107388A TW555533B (en) | 1998-10-22 | 2000-04-19 | Condensed drink having an inflammation-suppressing effect and an infectious-disease-preventive effect |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP3276929B2 (en) |
| TW (1) | TW555533B (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000239175A (en) * | 1999-02-18 | 2000-09-05 | Calpis Co Ltd | Antiallergic agent |
| JP4628508B2 (en) * | 1999-08-23 | 2011-02-09 | 株式会社伸栄フェルメンテック | Pain relief / removal agents and medical aids for pain relief / removal |
| WO2003022255A2 (en) * | 2001-09-05 | 2003-03-20 | Vsl Pharmaceuticals, Inc. | Lactic acid bacteria comprising unmethylated cytosine-guanine dinucleotides for use in therapy |
| WO2003056940A1 (en) * | 2002-01-08 | 2003-07-17 | Toshiyuki Hayakawa | Nutritional functional food and yeast/lactic acid bacterium parallel fermentationproduct ah21 |
| JP2004067599A (en) * | 2002-08-07 | 2004-03-04 | Kunihiko Tominaga | In-vagina detergent |
| US20040057934A1 (en) * | 2002-09-20 | 2004-03-25 | Hisashi Fujimura | Therapeutic agent for treating retroviral infection |
| WO2004112773A1 (en) * | 2003-04-24 | 2004-12-29 | Shin-Jen Shiao | Pharmaceutical compositions used for immune disease treatment and improvement |
| JP4712289B2 (en) * | 2003-08-26 | 2011-06-29 | 株式会社エイ・エル・エイ | Immune promoting composition |
| WO2005032568A1 (en) * | 2003-10-03 | 2005-04-14 | Nihon Baio Kabushiki Kaisha | Immunopotentiator, antiulcer agent and processed foods comprising fermented soybean product and process for producing fermented soybean product |
| DE202004005959U1 (en) * | 2004-04-13 | 2004-07-08 | Greifenstein, Peter | drug |
| EP1945234B1 (en) * | 2005-09-23 | 2012-12-19 | Gwangju Institute of Science and Technology | Composition for preventing or treating arthritis comprising lactic acid bacteria and collangen as active ingredients |
-
1998
- 1998-10-22 JP JP32007898A patent/JP3276929B2/en not_active Expired - Fee Related
-
2000
- 2000-04-19 TW TW89107388A patent/TW555533B/en active
Also Published As
| Publication number | Publication date |
|---|---|
| JP3276929B2 (en) | 2002-04-22 |
| JP2000125810A (en) | 2000-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7012840B2 (en) | Lactic acid bacteria and their uses | |
| US8025911B2 (en) | Preventive and/or remedy for inflammatory bowel diseases | |
| TW555533B (en) | Condensed drink having an inflammation-suppressing effect and an infectious-disease-preventive effect | |
| JP7004774B2 (en) | Uses of Lactobacillus reuteri strain GKR1 for the preparation of compositions that reduce uric acid | |
| CN111212575A (en) | Composition for muscle building | |
| JPWO2006075558A1 (en) | Egg-derived bone strengthening composition | |
| JP7281031B2 (en) | Composition for ameliorating persistent attention deficit associated with aging | |
| CN108367034A (en) | Infection shielding agent towards baby | |
| KR101806720B1 (en) | Antibacterial-listeria composition of culture medium containing membranous milkvetch root fermented with lactobacillus plantarum | |
| JP2015070855A (en) | Fermented milk production method and antiviral agent production method | |
| Gooch et al. | Where tradition meets science: microbial diversity and bioactive compounds in Armenian fermented milk products | |
| KR102244732B1 (en) | Probiotic acetic acid bacteria Acetobacter pasteurianus MGLV and its immunomodulatory effect | |
| JP2004135669A6 (en) | A lactic acid bacterial strain named Pediococcus pentosaceus CBT-8, which produces an antibacterial active substance that suppresses the growth of Helicobacter pylori and Listeria monocytogenes, is used as an antibacterial bacterium. Method for producing antibacterial substance having bioactive agent and method for utilizing antibacterial substance for functional foods and pharmaceuticals | |
| US20220022516A1 (en) | Composition for Suppressing Norovirus Infection | |
| JP7267536B2 (en) | Method for producing lactic acid-fermented carrot | |
| KR20140026433A (en) | Agent for improving or maintaining qol | |
| JP2017197486A (en) | INTERFERON λ INDUCER | |
| JP6016326B2 (en) | Screening method for lactic acid bacteria | |
| JP6777911B2 (en) | Fermented milk for suppressing the decrease in immune function acquired by anti-influenza drugs and its manufacturing method | |
| JP3818073B2 (en) | Colorectal cancer expression inhibitor | |
| Abbo | Probiotic, starter culture and antimicrobal properties of lactic acid bacteria isolated from Ugandan traditional ghee | |
| Hayes | Bovine colostrum | |
| CN103717227A (en) | Clostridium difficile growth inhibitor | |
| WO2005087247A1 (en) | Blood cholesterol level-lowering agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GD4A | Issue of patent certificate for granted invention patent |